More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes.
DUBLIN, Ohio, December 9, 2021 — More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes. These findings were released today in the latest edition of Oncology Insights, a report published by Cardinal Health Specialty Solutions based on surveys with more than 240 US oncologists.
Anxiety disorders and depression were cited by more than 80% of oncologists as the types of mental health distress seen most frequently in their patients, but personality and addiction disorders were also mentioned. Despite the high prevalence of mental health concerns, only a third of the surveyed oncologists said they frequently refer patients for mental health treatment and nearly half say there are not adequate resources available to support the mental health needs of cancer patients.
"Recent research indicates that mental health generally has declined since the start of the COVID-19 pandemic. This is particularly concerning for patients with cancer who are already at an increased risk for mental health distress," said Heidi Hunter, president of Cardinal Health Specialty Solutions. "Our latest oncology survey shines a light on this issue and provides insights on additional education and resources that could help oncologists to provide much-needed support to patients."
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More